Refine by
Oncology Patient Articles & Analysis
79 news found
Medical science is witnessing remarkable advancements in neurology and oncology, with cutting-edge technologies shaping the future of patient care. ...
Bayer presents first Phase 1 results from its most advanced clinical Immuno-Oncology program, aryl hydrocarbon receptor (AhR) inhibitor BAY2416964 New preclinical data on Bayer’s DGK zeta inhibitor being featured in oral presentation in New Drugs on the Horizon session New preclinical data on mutEGFR HER2 program, currently in Phase 1, will be presented Bayer ...
ByBayer AG
Researchers at Dana-Farber Cancer Institute showed that enumeration of circulating tumor cells (CTCs) with Menarini Silicon Biosystems’ CELLSEARCH® System and the CELLSERCH® Circulating Multiple Myeloma Cell (CMMC) Test* can be used to monitor and manage patients with Multiple Myeloma (MM) even at asymptomatic precursor stages Menarini Silicon Biosystems, a pioneer of liquid biopsy ...
Stemline Therapeutics (“Stemline”), a wholly-owned subsidiary of the Menarini Group, headquartered in New York and focused on bringing transformational oncology treatments for cancer patients, will commercialize ORSERDU in the U.S. ...
“The support of our new investors along with the continued commitment of our existing investors and founders emphasizes our momentum and progress in defining precision immuno-oncology for new patient segments.” Juergen Eckhardt, MD, Head of Leaps by Bayer, commented, “Leaps by Bayer was founded to help solve ten of the world’s biggest ...
ByBayer AG
Indication Expansion: The Cellworks Platform can potentially identify additional indications where an investigational drug may be effective by leveraging the Cellworks patient database of 100,000+ omics patient profiles and 1,800 oncology cell-lines to evaluate the efficacy of the agent in other indications. ...
This Phase 3 programme is expected to include up to 2,000 patients and deliver a comprehensive data set supporting a clinical endpoint in Surgical Site Infection (“SSI”) reduction that is clinically and statistically significant. ...
(Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that the first 13 patients have been dosed in Part 1 of the pivotal Phase 3 SERENITY III trial investigating at-home use of BXCL501 (dexmedetomidine) sublingual film, the Company’s ...
” Founded in 2018, xCures currently stands at the forefront of innovation in how healthcare technology can benefit both patients with cancer and medical professionals in the field of oncology. ...
ByxCures
Oncology informatics company, Inspirata, is pleased to announce the recent addition of a new key member to the company’s leadership team. ...
The clinical trial, started in July 2022 and plans to recruit 50 patients eligible for immediate breast reconstruction in 8 centers in Europe. ...
SEATTLE, Sept. 27, 2022 (GLOBE NEWSWIRE) -- SEngine Precision Medicine Inc., a Seattle-based precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived 3D cultures, is conducting a Non-Small Cell Lung Cancer (NSCLC) study at the esteemed Johns Hopkins University. ...
Inthis way, avery low radioactive doseis needed, much lower than the one used with conventionalradio-metabolic treatments, thus enhancing treatment efficacy and patient safety. BAT-90opens up important horizons in oncology, bringing benefits to both patients andhealthcare systems. Indeed, BAT-90 is atherapeutic nuclear medicinesolution that is ...
BAT-90 BetaGlue has developed and patented BAT-90 ("Beta Ablation Therapy with Yttrium-90"), consisting of a p radiation-emitting biocompatible matrix, delivered to patients via percutaneous injection or during surgery: the Yttrium-90-labelled microspheres present inside the matrix are injected into the tumour and, as the carrier need few seconds to reach full polymerisation, ...
The first clinical results have shown that BAT-90 innovative radiotherapy platform makes it possible to treat only the area where the tumour is located, while avoiding the surrounding tissues, so as to combine treatment efficacy and patient safety CEO/CMO, Dr. Antonino Amato, said: "The confirmation in this first patient of the previous findings from the ...
(Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today the establishment of a Scientific Advisory Board (SAB) of renowned experts in their respective fields to provide scientific and clinical guidance on the development ...
Representing a total $140M USD investment into the area, Bayer’s 62,100-square-foot building houses a new center of precision molecular oncology research equipped with state-of-the-art laboratories and offices for the development of novel targeted cancer therapies for patients. ...
ByBayer AG
It has the potential to revolutionize radiation oncology, having demonstrated compelling success in some of the most difficult-to-treat cancers and in treating patients for whom all other treatment options have been exhausted. ...
It has the potential to revolutionize radiation oncology, having demonstrated compelling success in some of the most difficult-to-treat cancers and in treating patients for whom all other treatment options have been exhausted. ...
(Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today presented a poster at the Annual Meeting of the European Hematology Association (EHA) in Vienna, Austria. ...